Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.
We examined the ability of the antiparkinsonian agent (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) to enter the systemic circulation in therapeutic concentrations after continuous transdermal absorption in squirrel monkeys rendered parkinsonian by MPTP. Direct subcutaneous administration of (+)-PHNO i...
| Hoofdauteurs: | , , , , , , , , |
|---|---|
| Formaat: | Journal article |
| Taal: | English |
| Gepubliceerd in: |
1989
|
| _version_ | 1826303391273320448 |
|---|---|
| author | Rupniak, N Tye, S Jennings, C Loper, A Bondi, J Hichens, M Hand, E Iversen, S Stahl, S |
| author_facet | Rupniak, N Tye, S Jennings, C Loper, A Bondi, J Hichens, M Hand, E Iversen, S Stahl, S |
| author_sort | Rupniak, N |
| collection | OXFORD |
| description | We examined the ability of the antiparkinsonian agent (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) to enter the systemic circulation in therapeutic concentrations after continuous transdermal absorption in squirrel monkeys rendered parkinsonian by MPTP. Direct subcutaneous administration of (+)-PHNO in the dose range of 2.5 to 20 micrograms/kg restored locomotor activity to levels seen in normal monkeys for approximately 1 hour. Application of transdermal patches capable of delivering, into an infinite sink, an estimated 2.6 micrograms/cm2/h of (+)-PHNO over a skin surface area of 4.78 to 19.12 cm2 also restored locomotor activity to the normal range during a 24-hour period. We suggest the use of transdermal application of PHNO as a novel drug delivery system for the improved management of Parkinson's disease. |
| first_indexed | 2024-03-07T06:01:58Z |
| format | Journal article |
| id | oxford-uuid:ec802831-c116-4117-9e21-0573e6f43ab2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:01:58Z |
| publishDate | 1989 |
| record_format | dspace |
| spelling | oxford-uuid:ec802831-c116-4117-9e21-0573e6f43ab22022-03-27T11:18:12ZAntiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ec802831-c116-4117-9e21-0573e6f43ab2EnglishSymplectic Elements at Oxford1989Rupniak, NTye, SJennings, CLoper, ABondi, JHichens, MHand, EIversen, SStahl, SWe examined the ability of the antiparkinsonian agent (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) to enter the systemic circulation in therapeutic concentrations after continuous transdermal absorption in squirrel monkeys rendered parkinsonian by MPTP. Direct subcutaneous administration of (+)-PHNO in the dose range of 2.5 to 20 micrograms/kg restored locomotor activity to levels seen in normal monkeys for approximately 1 hour. Application of transdermal patches capable of delivering, into an infinite sink, an estimated 2.6 micrograms/cm2/h of (+)-PHNO over a skin surface area of 4.78 to 19.12 cm2 also restored locomotor activity to the normal range during a 24-hour period. We suggest the use of transdermal application of PHNO as a novel drug delivery system for the improved management of Parkinson's disease. |
| spellingShingle | Rupniak, N Tye, S Jennings, C Loper, A Bondi, J Hichens, M Hand, E Iversen, S Stahl, S Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. |
| title | Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. |
| title_full | Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. |
| title_fullStr | Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. |
| title_full_unstemmed | Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. |
| title_short | Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. |
| title_sort | antiparkinsonian efficacy of a novel transdermal delivery system for phno in mptp treated squirrel monkeys |
| work_keys_str_mv | AT rupniakn antiparkinsonianefficacyofanoveltransdermaldeliverysystemforphnoinmptptreatedsquirrelmonkeys AT tyes antiparkinsonianefficacyofanoveltransdermaldeliverysystemforphnoinmptptreatedsquirrelmonkeys AT jenningsc antiparkinsonianefficacyofanoveltransdermaldeliverysystemforphnoinmptptreatedsquirrelmonkeys AT lopera antiparkinsonianefficacyofanoveltransdermaldeliverysystemforphnoinmptptreatedsquirrelmonkeys AT bondij antiparkinsonianefficacyofanoveltransdermaldeliverysystemforphnoinmptptreatedsquirrelmonkeys AT hichensm antiparkinsonianefficacyofanoveltransdermaldeliverysystemforphnoinmptptreatedsquirrelmonkeys AT hande antiparkinsonianefficacyofanoveltransdermaldeliverysystemforphnoinmptptreatedsquirrelmonkeys AT iversens antiparkinsonianefficacyofanoveltransdermaldeliverysystemforphnoinmptptreatedsquirrelmonkeys AT stahls antiparkinsonianefficacyofanoveltransdermaldeliverysystemforphnoinmptptreatedsquirrelmonkeys |